>_ QFI Terminal
TerminalStocks › ENVB

Enveric Biosciences, Inc. (ENVB) Stock

Healthcare · Biotechnology · US
$3.88 -24.81%
Last updated Sep 20, 2026 14:59 UTC

ENVB Key Statistics

Market Cap$2.32M
P/E (TTM)0.00
P/S (TTM)
P/B (TTM)0.99
Revenue (TTM)$0.00
EPS (TTM)$-14,610.70
Dividend Yield
ROE (TTM)-255.44%
Net Margin0.00%
Gross Margin0.00%
52W High$7.88
52W Low$1.71
Analyst ViewBuy
Price Target
Employees5
Volume2,797,982

About Enveric Biosciences, Inc.

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

CEO: Joseph Edward Tucker. Company website

ENVB — Frequently Asked Questions

What is the ENVB stock price today?

Enveric Biosciences, Inc. (ENVB) trades at $3.88, down 24.81% on the day, as of Sep 20, 2026 14:59 UTC.

What is Enveric Biosciences, Inc.'s market cap?

Enveric Biosciences, Inc. has a market capitalisation of $2.32M, calculated from the live ENVB share price and shares outstanding.

What is the P/E ratio of ENVB?

ENVB has no meaningful price-to-earnings ratio: Enveric Biosciences, Inc. lost $14,610.70 per share over the last twelve months, and a P/E is only defined on positive earnings.

How much revenue does Enveric Biosciences, Inc. make?

Enveric Biosciences, Inc. generated revenue of $0.00 over the trailing twelve months.

What is the 52-week range for ENVB?

ENVB has traded between $1.71 and $7.88 over the past 52 weeks, and the last price is 50.8% below that high.

Is Enveric Biosciences, Inc. profitable?

Yes. Enveric Biosciences, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.

What is the analyst price target for ENVB?

Wall Street analysts rate ENVB Buy.

What sector is Enveric Biosciences, Inc. in?

Enveric Biosciences, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .

Who is the CEO of Enveric Biosciences, Inc.?

Joseph Edward Tucker is the chief executive of Enveric Biosciences, Inc., which employs 5 people.

Where can I track ENVB in real time?

QFI Terminal shows ENVB with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.

See ENVB live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open ENVB in Terminal See plans

Biotechnology stocks

REGN Regeneron Pharmaceuticals, Inc. VRTX Vertex Pharmaceuticals Incorporated ONC BeOne Medicines AG ARGX argenx SE INCY Incyte Corporation ALNY Alnylam Pharmaceuticals, Inc. JAZZ Jazz Pharmaceuticals plc GMAB Genmab A/S

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corp. MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. ELV Elevance Health Inc.